The psychedelic medicine sector experienced a broad market rally on February 17, 2026, following breakthrough data from Compass Pathways. The company reported successful results for its synthetic psilocybin candidate, COMP360, setting the stage for a New Drug Application (NDA) with the FDA planned for the fourth quarter of 2026.
Data from two late-stage clinical trials demonstrated that COMP360 was effective and well-tolerated for treatment-resistant depression. Notably, a second administration of the therapy led to significant remission rates in a specific patient subset. By the sixth week of the trial, participants receiving the 25mg dose showed a 3.8-point improvement on a standardized depression scale compared to the control group.
The positive news acted as a catalyst for the entire industry. Compass Pathways’ shares surged by more than 50%, while GH Research and Helus Pharma saw gains of nearly 12%. Other key players, including AtaiBeckley and Definium Therapeutics (formerly MindMed), saw their stock prices rise between 5% and 8%. Analysts suggest these results validate the scalability of psychedelic-based treatments for complex mental health conditions, representing a major commercial opportunity in the central nervous system market.